Profile: ACADIA Pharmaceuticals Inc (ACAD.O)
26 May 2017
ACADIA Pharmaceuticals Inc., incorporated on January 16, 1997, is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. The Company's lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist (SSIA), preferentially targeting 5-HT2A receptors.
The Company is conducting a Phase II trial, referred to as the SERENE Study, designed to examine the efficacy and safety of pimavanserin as a treatment for Alzheimer's disease (AD) Agitation. It is also conducting a Phase III, six-week, randomized, double-blind, placebo-controlled, multi-center, outpatient study, referred to as the ENHANCE-1 study, designed to examine the use of pimavanserin in patients with schizophrenia. It is conducting a Phase II, 26-week, randomized, double-blind, placebo-controlled, multi-center study, referred to as the ADVANCE study, designed to examine the use of pimavanserin in patients with schizophrenia, having predominant negative symptoms. It is also conducting a Phase II, 10-week, randomized, double-blind, placebo-controlled, multi-center study, referred to as the CLARITY study, designed to examine the use of pimavanserin in patients with major depressive disorder, having an inadequate response to standard antidepressant therapy with either a selective serotonin reuptake inhibitor (SSRI) or a serotonin norepinephrine reuptake inhibitor (SNRI).
The Company competes with Eisai Inc., Pfizer Inc., Actavis plc, Otsuka Pharmaceutical Co., Ltd., Sunovion Pharmaceuticals Inc. and Eli Lilly.
ACADIA Pharmaceuticals Inc
3611 Valley Centre Dr Ste 300
SAN DIEGO CA 92130-3331